Study Objectives: Tryptophan metabolism via the kynurenine pathway may represent a key molecular link between sleep loss and cognitive dysfunction. Modest increases in the kynurenine pathway metabolite kynurenic acid (KYNA), which acts as an antagonist at N-methyl-d-aspartate and α7 nicotinic acetylcholine receptors in the brain, result in cognitive impairments. As glutamatergic and cholinergic neurotransmissions are critically involved in modulation of sleep, our current experiments tested the hypothesis that elevated KYNA adversely impacts sleep quality. Methods: Adult male Wistar rats were treated with vehicle (saline) and kynurenine (25, 50, 100, and 250 mg/kg), the direct bioprecursor of KYNA, intraperitoneally at zeitgeber time (ZT) 0 to rapidly increase brain KYNA. Levels of KYNA in the brainstem, cortex, and hippocampus were determined at ZT 0, ZT 2, and ZT 4, respectively. Analyses of vigilance state-related parameters categorized as wake, rapid eye movement (REM), and non-REM (NREM) as well as spectra power analysis during NREM and REM were assessed during the light phase. Separate animals were tested in the passive avoidance paradigm, testing contextual memory. Results: When KYNA levels were elevated in the brain, total REM duration was reduced and total wake duration was increased. REM and wake architecture, assessed as number of vigilance state bouts and average duration of each bout, and theta power during REM were significantly impacted. Kynurenine challenge impaired performance in the hippocampal-dependent contextual memory task. Conclusions: Our results introduce kynurenine pathway metabolism and formation of KYNA as a novel molecular target contributing to sleep disruptions and cognitive impairments.
INTRODUCTION
The essential amino acid tryptophan and its metabolic products, serotonin and melatonin, are implicated in regulating sleep and have been used to treat insomnia and sleep apnea. [1] [2] [3] [4] [5] As only about 5% of tryptophan is degraded via serotonin metabolism, the vast majority of tryptophan is metabolized in the kynurenine pathway, 6 which is responsible for the synthesis of the neuroinhibitory molecule kynurenic acid (KYNA). However, the direct relationship between sleep and the kynurenine pathway has remained largely unexplored.
KYNA, an endogenous neuromodulator derived locally in the brain within astrocytes, is implicated in cognitive processes in health and disease. 7 Over the years, translational research has focused specifically on the impact of KYNA fluctuations on modulating cognitive behaviors, as KYNA acts as an inhibitor at glutamate receptors, including N-methyl-d-aspartate (NMDA), kainate, and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and α7 nicotinic acetylcholine (α7nACh) receptors in the brain. [7] [8] [9] An array of preclinical studies has introduced the notion that elevations in brain KYNA levels cause deficits, whereas reductions in KYNA cause improvements in learning and memory. 7, [10] [11] [12] Specifically, nanomolar or low micromolar concentrations of KYNA itself, or stimulation of KYNA synthesis with the direct bioprecursor kynurenine, cause disruptions in hippocampus-mediated learning and memory in rodents. 7, 10, 13 Conversely, decreases in brain KYNA levels, by pharmacological inhibition or genetic knock-out of the synthesizing enzyme kynurenine aminotransferase (KAT) II, are associated with pro-cognitive effects in hippocampus-based cognitive tasks. [10] [11] [12] The association between excessive levels of brain KYNA and cognitive impairments is also bolstered by animal studies, wherein modest elevations in brain KYNA modulate glutamatergic and cholinergic neurotransmissions. 8, [14] [15] [16] As both neurotransmitter systems are critically involved in cognitive function 17, 18 and sleep-dependent plasticity [19] [20] [21] [22] and have been implicated in modulation of sleep-wake behavior, [23] [24] [25] [26] [27] [28] we hypothesize that elevated KYNA adversely impacts sleep quality and cognitive function.
To address this hypothesis, we tested the impact of endogenous KYNA elevation on sleep-wake behavior and learning in a contextual memory task. As most behavioral studies that have linked KYNA elevation with neurocognitive impairments were conducted in the light phase, 7, 10, 13, 29, 30 during which the majority of rodent sleep is accumulated, we administered the bioprecursor kynurenine, to rapidly elevate KYNA, at the beginning of the light cycle. Biochemical analysis of brain areas, including brainstem, cortex, and hippocampus, was conducted to determine the time-course and dose-dependent elevation of KYNA. To assess sleep, rats were implanted with telemetric devices to acquire polysomnographic recordings that combine electroencephalogram (EEG) and electromyogram (EMG). The sleep states, consisting of nonrapid eye movement (NREM) and rapid eye movement (REM), and wake behavior were assessed. Finally, in separate animals, KYNA levels were elevated on the training day of the passive avoidance paradigm, and retrieval of the newly formed contextual memory was assessed the next day.
We report that acute kynurenine challenge adversely affects REM sleep, in a dose-dependent manner, and increases wake behavior, resulting in a disruption of the normal sleep architecture during the light phase. Taken together with impairments in the hippocampal-dependent memory task, our data suggest that acute elevations in KYNA induce sleep disruptions that correlate with cognitive impairments.
METHODS

Animals
Adult, male Wistar rats (250-350 g), obtained from Charles River Laboratories (Frederick, MD) were used in all experiments. Separate cohorts of animals were used for biochemical analysis, sleep-wake recordings, and behavioral experiments. The animals were housed in a temperature-controlled facility at the Maryland Psychiatric Research Center. They were kept on a 12/12-hour light-dark cycle, with lights on = zeitgeber time (ZT) 0 and lights off = ZT 12. Animals received ad libitum access to food and water for the duration of the experiment. The facility was fully accredited by the American Association for the Accreditation of Laboratory Animal Care. Our experimental protocols were approved by the University of Maryland Institutional Animal Care and Use Committee and followed the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Chemicals l-Kynurenine sulfate ("kynurenine", purity 99.4%) was obtained from Sai Advantium (Hyderabad, India). Other chemicals were obtained from various suppliers and were of the highest commercially available purity. For intraperitoneal (i.p.) injections, kynurenine was dissolved in sterile, phospho-buffered saline, and pH was adjusted to 7.0 with 0.1 N NaOH.
Biochemical Analysis
Animals were treated acutely with saline (vehicle) or kynurenine (25, 50, 100, or 250 mg/kg, i.p.) at ZT 0. For tissue collection, all animals were euthanized by CO 2 asphyxiation. To determine basal kynurenine and KYNA levels, a group of saline-treated animals was euthanized immediately after i.p. injection at ZT 0. Subsequent cohorts of saline-and kynurenine-treated animals were euthanized at ZT 2 and ZT 4, respectively. Whole trunk blood was rapidly collected in tubes containing K 3 -EDTA (0.15%), and the brain was promptly removed. The blood was centrifuged (300 × g, 10 minutes) to separate plasma from blood cells, and the supernatant was removed and frozen at −80°C. The brain was promptly snap-frozen and stored at −80°C. On the day of the assays, the brain samples were dissected into hemi-forebrain, brainstem, cortex, and hippocampus. The brain regions were weighed and then sonicated (1:10, w/v) in ultrapure water and aliquoted for the determination of KYNA.
Plasma samples were thawed and diluted 1:2, in ultrapure water, to determine kynurenine. One hundred microliters of diluted sample were acidified with 25 µL of 25% perchloric acid. After centrifugation (12 000 × g, 10 minutes), 20 µL of the supernatant was subjected to high-performance liquid chromatography (HPLC) to determine content of kynurenine in the plasma and KYNA in the brain regions. Kynurenine and KYNA were isocratically eluted from a ReproSil-Pur C18 column (4 × 150 mm; Dr. Maisch GmbH, Ammerbuch, Germany), using a mobile phase containing 50-mM sodium acetate and 5% acetonitrile (pH adjusted to 6.2 with glacial acetic acid) at a flow rate of 0.5 ml/minute, and detected fluorimetrically in the eluate with 500-mM zinc acetate delivered after the column with a flow rate of 0.1 mL/minute. In the eluate, kynurenine (excitation 365 nm, emission 480 nm) and KYNA (excitation 344 nm, emission 398 nm) were detected fluorimetrically (Waters Alliance, 2475 fluorescence detector, Bedford, MA) at a retention time of ~6 and 12 minutes, respectively.
Surgery
The telemeter and EEG/EMG electrodes were surgically implanted according to the previously published protocols. [31] [32] [33] Briefly, animals were anesthetized using isoflurane and placed in a David Kopf (Tujunga, CA) stereotaxic frame to secure the head. The telemetry transmitters (TL11M2-F40-EET; Data Science International, St. Paul, MD) were intraperitoneally implanted through a dorsal incision of the abdominal region. This incision was stapled closed with wound clips. Another incision at the midline of the head and neck was made to expose the skull and neck muscle. Two burr holes (0.5 mm diameter) were drilled asymmetrically and two dental screws (Plastics One, Roanoke, VA) were implanted at 2.0 mm anterior/+1.5 mm lateral and 7.0 mm posterior/−1.5 mm lateral relative to bregma. EEG leads were wrapped around the screws and secured with dental cement (Stoelting Co., Wood Dale, IL). The two EMG leads were inserted directly into the dorsal cervical neck muscle at ~1.0 mm apart and sutured into place. The skin along the head was sutured. Animals were allowed to recover postoperatively for ≥6 days before the start of experiments.
Sleep Data Acquisition and Analysis
Each animal in the sleep monitoring study received vehicle and kynurenine (25, 50 , 100, or 250 mg/kg i.p.), administered on two consecutive days at the beginning of the light cycle, ZT 0. A counterbalanced design was used to test the impact of the lowest and highest dose of kynurenine (25 and 250 mg/kg, respectively) on sleep-wake parameters, with ≥7 days between recordings. Separate cohorts of animals were used for 50 and 100 mg/kg kynurenine. All sleep data were recorded in a designated room. EEG and EMG waveform data were continuously collected using either Dataquest ART 4.0 software (DSI) or Ponemah 6.10 software (DSI). Digitized signal data were scored offline with Neuroscore 3.0 (DSI) in 10-second epochs as wake (low-amplitude, high-frequency EEG combined with high-amplitude EMG), NREM (high-amplitude, low-frequency EEG with low-amplitude EMG), or REM (low-amplitude, high-frequency EEG with very low EMG tone).
Vigilance state parameters that were assessed included the total duration, average bout length, average number of bouts, the number of transitions between vigilance states, and home cage activity during wakefulness. A bout was defined as an uninterrupted episode of a single behavioral state lasting for at least one full epoch.
The DSI module for powerbands in NeuroScore was used to generate power frequencies present in REM and NREM. The discrete fast Fourier transform (DFT) was used to calculate the EEG power spectrum for the following frequency bandwidths: delta (0.5-4 Hz), theta (4-8 Hz), alpha (8) (9) (10) (11) (12) , sigma (12) (13) (14) (15) (16) , and beta (16) (17) (18) (19) (20) . DFT power spectrum analysis was assessed for 6-hour bins of the light cycle.
Contextual Memory Test
The passive avoidance paradigm was used to assess contextual memory. The apparatus had two compartments of equal size (each 21.3-cm high, 20.3-cm wide, and 15.9-cm deep) separated by a guillotine door (Med Associates, St. Albans, VT). The left compartment was illuminated and the right compartment remained dark. On the training day at ZT 0, animals received either vehicle or kynurenine (25, 50 , 100, or 250 mg/kg, i.p.). Animals were placed back into their home cage and left undisturbed until the training session at ZT 2. At the time of training, each animal was placed first in the illuminated compartment. The guillotine door was opened, the rat naturally moved into the preferred dark compartment, and the latency to enter was recorded. After the door was closed, an inescapable foot shock (0.57 mA for 1 second) was delivered through the metal floor rods. Twenty-four hours later, at ZT 2, during the testing trial, the retention of the newly formed aversive foot shock memory was tested. Each animal was again placed in the illuminated compartment, the guillotine door was opened, and the latency to enter the dark compartment was recorded. The fold change in latency, denoted as the avoidance latency during the testing trial over the approach latency during the training trail, was calculated and analyzed.
Statistical Analysis
For biochemical analyses, comparisons were made using a two-way analysis of variance (ANOVA) with treatment group and ZT as between-subject factors. Vigilance state data (REM, NREM, wake duration, bout number, average bout duration, and transitions between vigilance states) and power data were analyzed by two-way repeated-measures ANOVA comparing vehicle and kynurenine treatment. For behavioral data, comparisons were made using ANOVA. Where appropriate, significant effects were followed up with Fisher LSD post hoc analysis (dose-response biochemistry, sleep EEG, and behavior) or Bonferroni t test correction (100 mg/kg EEG data), with an adjusted alpha for number of comparisons. Statistical significance was defined as p < .05. All statistical analyses were performed using GraphPad Prism 6.0 software.
RESULTS
Kynurenine Challenge at Start of Light Cycle Increases Brain KYNA Levels
We first determined the impact of acute kynurenine challenge (25, 50, 100, or 250 mg/kg, i.p.) at ZT 0, the start of the light cycle, on plasma kynurenine and brain KYNA levels at ZT 2 and ZT 4 (N = 4 − 5 per group). Immediately after vehicle treatment, a cohort of animals was killed at ZT 0 to determine baseline levels of plasma kynurenine (8 ± 0.5 µM) ( Figure  1A ), brainstem KYNA (117 ± 20 fmol/mg protein) ( Figure  1B ), cortex KYNA (66 ± 2 fmol/mg protein) ( Figure 1C ), and hippocampus KYNA (52 ± 3 fmol/mg protein) ( Figure 1D ). Within vehicle-treated animals, no significant effect of time (ZT 0, ZT 2, or ZT 4) was observed for plasma kynurenine (F 2,12 = 1.38, p = .29) or KYNA in brainstem (F 2,12 = 0.63, p = .55), cortex (F 2,11 = 1.97, p = .19), or hippocampus (F 2,12 = 0.87, p = .44). Plasma kynurenine levels were significantly impacted by kynurenine treatment (F 4,38 = 38.74, p < .0001) and time (F 4,38 = 73.94, p < .0001), and there was also a significant treatment × time interaction (F 4,38 = 22.48, p < .0001). Two hours after treatment, kynurenine treatment caused a dose-dependent increase in plasma kynurenine compared with vehicle treatment at ZT 2 (25 mg/kg: 1.3-fold, 50 mg/kg: 2.7-fold, 100 mg/ kg: 8.4-fold, and 250 mg/kg: 11.8-fold), with a statistically significant elevation at the two highest doses of kynurenine. By ZT 4, kynurenine levels in the plasma of kynurenine-treated rats were reduced compared with kynurenine-treated rats at ZT 2. Notably, plasma kynurenine remained elevated at ZT 4 compared with vehicle treatment in the animals that received either 100 mg/kg (3.1-fold) or 250 mg/kg (2.4-fold) kynurenine ( Figure 1A ).
In the brain, we examined KYNA levels in the brainstem, cortex, and hippocampus. Kynurenine treatment significantly impacted KYNA levels in all three brain regions (brainstem: treatment × time, Figure 1D ). Notably, while in all three brain regions, the two higher doses of kynurenine (100 and 250 mg/ kg) caused a significant elevation in KYNA compared with vehicle-treatment, hippocampal KYNA was also significantly elevated with peripheral injection of 25 or 50 mg/kg kynurenine. In addition, at ZT 4, KYNA levels remained significantly elevated in 250 mg/kg kynurenine-treated rats compared with controls in the brainstem (1.7-fold) ( Figure 1B) , cortex (1.8-fold) ( Figure 1C ), and hippocampus (3.2-fold) ( Figure 1D ), as well as in the cortex of animals that received 100 mg/kg kynurenine (1.9-fold).
Kynurenine Treatment Negatively Impacts REM Sleep and Increases Wake
Separate cohorts of animals (N = 6 − 8) were used for sleep monitoring experiments, wherein vehicle and kynurenine (25, 50 , 100, or 250 mg/kg i.p.) were administered on two consecutive days at the beginning of the light cycle, ZT 0. A main-effect of treatment revealed that on the day that animals received kynurenine, the onset of REM was significantly delayed (F 1,26 = 9.52, p < .01), and a post hoc significant difference was detected within subjects that received 100 mg/kg kynurenine (vehicle: 26 ± 5 minutes; kynurenine: 49 ± 10 minutes, p < .05). NREM sleep onset was not significantly impacted by kynurenine treatment (F 1,26 = 0.79, p < .01) ( Table 1) .
To assess the impact of kynurenine on sleep-wake duration, the percent change from vehicle was calculated. Guided by the biochemical data that showed the highest elevations in brain KYNA until ZT 2, sleep-wake duration data were initially analyzed in the bin from ZT 0 − ZT 2. During this two hour window (Figure 2A ), kynurenine treatment significantly reduced REM duration (F 1,26 = 15.36, p < .001) in a dose-dependent manner (F 3,26 = 3.33, p < .05), with statistically significant reductions at 100 and 250 mg/kg kynurenine. NREM duration was also significantly impacted by kynurenine treatment (F 1,26 = 5.60, p < .05), and post hoc analysis revealed a significant reduction from vehicle treatment with 100 mg/kg kynurenine. The reductions in sleep duration were paired with an increase in wake duration as a result of kynurenine treatment (F 1,26 = 10.11, p < .01) and a significant treatment × dose interaction (F 3,26 = 3.91, p < .05). Post hoc analysis indicated that 100 mg/kg kynurenine significantly increased wake duration during this 2-h period.
To understand the broader impact of kynurenine treatment on sleep-wake duration, the percent change from vehicle was also assessed for the entire duration of the light phase (ZT 0 − ZT 12) and dark phase (ZT 12 − ZT 24). During the light phase ( Figure 2B ), kynurenine treatment significantly affected REM duration (F 1,26 = 5.87, p < .05), in a dose-dependent manner (F 3,26 = 34.05, p < .0001), and post hoc analysis revealed a significant reduction in the percent change from vehicle with 100 and 250 mg/kg kynurenine. No main effect of kynurenine treatment on NREM duration was observed for the entire duration of the light cycle (F 1,26 = 2.59, p = .12). However, kynurenine treatment (F 1,26 = 5.05, p < .05) and dose (F 3,26 = 7.00, p < .01) significantly impacted wake duration during the light cycle, and post hoc analysis showed a significant increase in duration. Post hoc analysis of the NREM data showed a significant increase in NREM duration with 100 mg/kg kynurenine treatment compared with vehicle treatment.
As the most profound changes to vigilance state duration occurred during ZT 0 − ZT 2 (see Figure 2A) , the impact of various doses of kynurenine treatment on sleep-wake architecture was assessed during this period (Table 2) . Kynurenine treatment had a significant impact on the average duration of each wake episode (F 1,26 = 4.61, p < .05) and a significant treatment × dose interaction (F 3,26 = 4.32, p < .05) but did not significantly impact average duration of each REM episode (F 1,25 = 0.27, p = .60) or NREM episode (F 1,26 = 0.03, p = .86). Post hoc analysis revealed that specifically 100 mg/kg kynurenine treatment significantly increased the average duration of each wake bout. Analysis of the number of bouts into each vigilance state revealed a profound impact of kynurenine treatment on total number of REM bouts (F 1,26 = 11.93, p < .001), in a dose-dependent manner (F 3,26 = 4.76, p < .01), and significant reductions were observed post hoc with 50, 100, and 250 mg/kg kynurenine. No significant effects of kynurenine treatment on total numbers of NREM (F 1,26 = 2.03, p = .17) and wake (F 1,26 = 0.12, p = .73) bouts were observed.
To assess whether kynurenine challenge impacted the stability of maintaining a wake or sleep episode, the number of transitions into and out of wake, NREM sleep, and REM sleep was quantified. At the start of the light phase, ZT 0 − ZT 2, kynurenine treatment significantly reduced the number of transitions from NREM to REM (F 1,26 = 5.47, p < .05), in a dose-dependent manner (F 3,26 = 7.12, p < .01), and significant post hoc differences were noted with 100 and 250 mg/kg kynurenine (Table 3) . No significant impacts of kynurenine treatment on transitions were observed for the entire duration of the light phase or dark phase (Supplementary Table S1 ).
Taken together, we have identified significant changes to sleep-wake duration and architecture after kynurenine treatment. The most drastic impact on these measures occurred with 100 mg/kg kynurenine treatment; thus, we proceeded with a more thorough investigation of sleep-wake architecture with this dose. During the light phase, kynurenine (100 mg/ kg) treatment significantly impacted the total duration of REM (F 1,42 = 10.59, p < .01) ( Figure 3A) , average duration of each episode (F 1,42 = 0.94, p = .34) (Figure 3B ), and total number of REM episodes (F 1,42 = 4.33, p < .05) ( Figure 3C ) when assessed across 2-h bins. Post hoc analysis showed a specific reduction in REM duration during ZT 0 − ZT 2 (p <.01) and ZT 2 − ZT 4 (p < .05). The average bout duration and total number of REM bouts were significantly reduced at ZT 0 − ZT 2 (p < .05). When the entire light phase was assessed, total REM duration (vehicle: 30 ± 3 minutes; kynurenine: 22 ± 1 minutes, p < .05) ( Figure 3D ) was also significantly reduced with kynurenine treatment compared with vehicle treatment. The average bout duration (vehicle: 54 ± 4 seconds; kynurenine: 51 ± 4 seconds, p = .40) ( Figure 3E ) and the number of total REM bouts during the light phase were not significantly impacted by kynurenine treatment (vehicle: 33 ± 3; kynurenine: 29 ± 2, p = .17) ( Figure 3F ).
As is typically observed in rodents, we found that ZT significantly impacted NREM duration (F 5,42 = 6.19, p < .001) ( Figure 4A ), average NREM bout duration (F 5,42 = 4.65, p < .01) ( Figure 4B ), and number of NREM bouts (F 5,42 = 3.34, p < .05) ( Figure 4C ) across 2-hour bins of the light phase. While there was no main effect of kynurenine treatment (100 mg/ kg) on NREM measures, there was a significant time × treatment interaction with respect to duration (F 5,42 = 2.99, p < .05), and post hoc analysis revealed significantly reduced NREM duration during the first 2-hour bin, ZT 0 − ZT 2 (p < .05). Analysis of the entire light phase revealed no significant changes to NREM duration (vehicle: 411 ± 13 minutes; kynurenine: 401 ± 9 minutes, p = .29) (Figure 4D ), NREM bout duration (vehicle: 169 ± 6 seconds; kynurenine: 178 ± 8 seconds, p = .06) (Figure 4E ), or number of NREM bouts (vehicle: 150 ± 3, kynurenine: 144 ± 4, p = .11) ( Figure 4F ).
With increased ZT, wake duration (F 5,42 = 9.68, p < .0001) ( Figure 5A ), average wake bout duration (F 5,42 = 3.78, p < .01) ( Figure 5B), and number of wake bouts (F 5,42 = 4.99, p < .01) ( Figure 5C ) were significantly impacted. Acute kynurenine treatment (100 mg/kg) increased total wake duration (F 1,42 = 10.20, p < .01) and wake bout duration (F 1,42 = 7.55, p < .01), but no significant impact on total number of wake bouts (F 1,42 = 0.60, p = .44) was found. Post hoc analysis revealed differences between vehicle and kynurenine treatment in the first 2-hour bin, ZT 0 − ZT 2, with respect to wake duration and average bout duration during wake (p < .01). Analysis of the entire light phase revealed a significant increase in wake duration (vehicle: 242 ± 7 minutes; kynurenine: 268 ± 5 minutes, p < .05) (Figure 5D ), wake bout duration (vehicle: 111 ± 4 seconds; kynurenine: 136 ± 5 seconds, p < .01) ( Figure 5E ), and no significant impact on total number of wake bouts (vehicle: 137 ± 4; kynurenine: 133 ± 3, p = .33) ( Figure 5F ). For the duration of the recording, kynurenine treatment did not significantly impact general home cage activity (F 1,7 = 0.25, p = .63), but as typically observed in rodents, activity with increased with ZT (F 11,77 = 13.06, p < .001) (Supplementary Figure S1) .
Sleep EEG Power Spectra
To assess the impact of kynurenine treatment (100 mg/kg) on the sleep power spectra, total REM and NREM power were assessed in 6-hour intervals of the light phase. During both intervals of the light phase, theta power during REM was increased compared with power in four other EEG frequency bands assessed-delta, alpha, sigma, and beta (ZT 0 − ZT 6: F 39,273 = 42.04, p < .0001) (ZT 7 − ZT 12: F 39,273 = 48.79, p < .0001). During NREM, delta power was increased compared with theta, alpha, sigma, and beta (ZT 0 − ZT 6: F 39,273 = 87.01, p < .0001) (ZT 7 − ZT 12: F 39,273 = 104.8, p < .0001). During the first half of the light phase, kynurenine treatment significantly impacted REM power when compared with vehicle (F 1,7 = 8.92, p < .05), and there was a significant treatment × power interaction (F 39,273 = 1.78, p < .01) ( Figure 6A ). During the latter half of the light cycle, the main effect of kynurenine treatment on REM power was no longer significantly different from vehicle treatment (F 1,7 = 0.11, p = .75), but a treatment × power interaction remained (F 39,273 = 1.58, p < .05) (data not shown). Post hoc analysis revealed a specific reduction in theta power frequency during REM after kynurenine treatment (p < .05). NREM power was not impacted by kynurenine treatment during either the first half (ZT 0 − ZT 6: F 1,7 = 0.38, p = .56) (Figure 6B ) or the latter half (ZT 7 − ZT 12: F 1,7 = 1.13, p = .32) (data not shown) of the light phase. A significant treatment × power interaction was observed only during the latter half of the light phase (ZT 7 − ZT 12: F 39,273 = 1.84, p < .01).
Kynurenine Challenge Impairs Contextual Memory Task
In an effort to understand the behavioral consequences of kynurenine challenge and observed REM sleep disturbances, we tested animals (N = 8 − 14 per group) in the passive avoidance paradigm to assess contextual memory. Animals received vehicle or kynurenine (25, 50, 100, or 250 mg/kg) at ZT 0 and were trained in the task at ZT 2. The latency to enter the dark compartment on the training day was not significantly impacted by kynurenine treatment (F 4,47 = 0.57, p = .68). Animals were then tested in the paradigm the next day at ZT 2. Vehicle-treated animals displayed significant contextual learning, evidenced as significantly higher latencies on the testing day (121 ± 27 seconds) compared with the training day (15 ± 3 seconds; p < .01). Of note, kynurenine treatment significantly impaired performance in the contextual memory task (F 4,47 = 4.17, p < .01), and post hoc analysis revealed that the fold change in testing day latency over training day latency was significantly reduced with 50, 100, and 250 mg/kg kynurenine compared with vehicle treatment (Figure 7 ), suggesting deficits in contextual learning.
DISCUSSION
In the present study, animals that were acutely challenged with kynurenine at the start of the light phase had dose-dependent elevations in endogenous KYNA in various brain regions, including the brainstem, cortex, and hippocampus. Kynurenine challenge also resulted in marked deficits in a contextual memory task. For the first time, telemetric EEG/EMG monitoring was conducted in rats after rapid KYNA elevation, and we report that sleep-wake architecture was significantly disrupted. Taken together, our findings suggest an interplay between brain KYNA, sleep, and cognitive function. We chose to investigate sleep architecture after acute peripheral kynurenine challenge based on several considerations. First, kynurenine is the initial bioproduct of tryptophan metabolism via the kynurenine pathway that catabolizes nearly 95% of tryptophan in mammalian cells. 6 While tryptophan has been extensively studied as a modulator of sleep, 1-5 the direct relationship between sleep and kynurenine pathway metabolism has been relatively unexplored. 34, 35 Second, from the blood, kynurenine readily enters the brain 36 and is then rapidly accumulated in astrocytes, 37, 38 wherein it is converted to KYNA. 39 The time course of this conversion in the brain has been studied with in vivo microdialysis studies that demonstrate a rapid increase in extracellular KYNA in several areas of the brain and validate peripheral kynurenine challenge as an experimental tool to endogenously elevate brain KYNA. 7, 29 Lastly, we intended to use peripheral kynurenine challenge to recapitulate an experimental condition, wherein moderate increases in brain KYNA cause a spectrum of cognitive deficits, including impairments in cognitive flexibility, 29 working memory, 30 contextual fear conditioning, 13 and spatial learning and memory, 7 with translational relevance.
In our first experiments, we verified the efficacy of acute kynurenine challenge by demonstrating a dose-dependent increase in plasma kynurenine levels after treatment. The elevation of KYNA in the brainstem, cortex, and hippocampus suggested a brain-wide biotransformation of kynurenine to KYNA. Levels of KYNA were the highest two hours after treatment, corresponding to ZT 2, and drastically decreased by ZT 
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. Thus, we demonstrate that kynurenine challenge acutely and reversibly elevates brain tissue KYNA, comparable with in vivo microdialysis studies. 7 Understanding this time course and dose response of KYNA elevation and subsequent washout is crucial when reviewing the impact of acute kynurenine challenge on sleep during the light phase.
Kynurenine treatment delayed REM onset on the day of treatment. Decreases in transitions from NREM to REM during ZT 0 to ZT 2 suggest a deficiency in initiating REM episodes, when KYNA levels are elevated. Implementation of a within animal design wherein each animal received vehicle and kynurenine deflates the notion that handling of the subject at the start of the light cycle was the reason for a delay in REM onset. The negative impact on REM was sustained for the entire duration of the light phase, in a dose-dependent manner, evidenced as decreased REM duration and impairments in REM architecture. Importantly, the loss of REM sleep was echoed by an increase in wakefulness during the light phase; however, the wake behavior was not characterized by an increase in home cage activity. Conceptually consistent with our findings, systemic KYNA treatment acutely reduced "active sleep" and increased wake behavior, quantified by body movements on a static charge sensitive mattress, in neonatal rats. 40 Notwithstanding the notion that sleep patterns differ from early postnatal development to adulthood, 41 our present study is in accordance with these findings as we report sleep disruptions after KYNA elevation and, with analysis of polysomnographic recordings, we decipher a specific inhibition of REM sleep and an increase in wakefulness. To obtain further insight into the changes in REM sleep, we examined the cortical EEG power spectra and found a significant reduction in the amplitude of theta power during REM after kynurenine treatment. As we discuss below, the paired reduction in REM duration and theta power may be contributing to the behavioral impairment we report after acute kynurenine challenge. To understand how KYNA could modulate sleep-wake behavior, some basic premises of KYNA neurobiology should be discussed. KYNA was originally characterized and behaviorally investigated as a nonspecific, broad-spectrum, antagonist at ionotropic excitatory amino-acid receptors at high micromolar concentrations in the brain. 9, 42 As mentioned above, in vivo microdialysis studies have demonstrated that KYNA is present in the extracellular milieu, albeit at submicromolar concentrations, 15, [43] [44] [45] [46] and is thus critically positioned to access membrane receptor targets on various cells of the brain. Presently, KYNA has been shown to potentiate signaling through the G protein-coupled receptor 35 47 and the aryl hydrocarbon receptor, 48 though the exact nature of these interactions in the brain remains to be elucidated. However, most research has focused on the ability of KYNA to competitively inhibit the glycine co-agonist site of the NMDA receptor 49 and block the allosteric potentiating site of the α7nACh receptor. 8, 14 As both α7nACh and NMDA receptors are critically involved in learning and memory, 17, 18 KYNA has been postulated to impact cognition via its inhibitory actions at these targets. 7 Alternatively, sleep-wake behaviors are also known to be modulated by glutamatergic and cholinergic neurotransmissions, [25] [26] [27] [28] and, in particular, high cholinergic neurotransmission is associated with REM sleep. [50] [51] [52] Thus, the robust decrease in REM, and impact and increase in wakefulness in rats after acute elevations in KYNA may also be explained by inhibition of these targets. The mechanism by which KYNA may be causally involved in bridging together sleep and cognition remains to be investigated.
Presently, we also show that acute KYNA elevation disrupts contextual memory the next day during the testing trial. The notion that sleep critically supports consolidation of a hippocampal-dependent memory is consistent with previous reports that have investigated the impact of sleep on memory consolidation in rodents. [53] [54] [55] [56] [57] [58] Importantly, it has been demonstrated that deep sleep preceding a task augments the hippocampus to encode new information. [59] [60] [61] Thus, the impairments in sleep induced by acute KYNA elevation prior to training (ZT 0 − ZT 2) as well as after training, the remainder of the light phase, in the contextual memory paradigm may both be contributing to the learning impairment. However, while the biochemical data show quantitative differences in KYNA formation between doses of kynurenine, the impacts on sleep-wake behavior and contextual memory were not meaningfully different between the two higher doses (100 and 250 mg/kg), suggesting perhaps a ceiling effect that may be related to the downstream targets of KYNA. 7 The notion that acute kynurenine challenge markedly reduced theta power during REM sleep for the entire light phase deserves special attention. Hippocampal theta oscillations are a hallmark phenotype of REM sleep and may contribute to memory consolidation by mechanistically strengthening place cells formed during prior wakefulness. [62] [63] [64] A recent study provided causal evidence for hippocampal theta rhythmicity in memory consolidation by optogenetic silencing of inhibitory neurons in the medial septum and blunting REM. Impressively, animals with suppressed REM sleep theta were impaired in a hippocampal-dependent memory task. 65 Taken together, we speculate that the combined impact of KYNA on theta power, coupled with a reduction in REM duration, contributes to memory impairments.
Our data provide further evidence of astrocytic modulation of sleep homeostasis, 66, 67 as KYNA is an endogenous astrocyte-derived metabolite. 39 As we used systemic administration of kynurenine, it is nonetheless important to consider a possible contribution of the alternative arm of the pathway that generates the metabolites 3-hydroxykynurenine, 3-hydroxyanthranilic acid, and quinolinic acid. 68 Even more compelling an argument for the role of KYNA in sleep will be to test an inhibitor of the KYNA synthesis enzyme KAT II in combination with kynurenine challenge, or to assess sleep-wake parameters in mouse models genetically modified to eliminate key kynurenine pathway enzymes.
11, 69 An additional limitation of our present study is the systematic increase in kynurenine pathway metabolism. Deciphering the specific circuitry and downstream targets of KYNA, including the α7nACh or NMDA receptors in the brain, will elucidate the mechanisms by which KYNA impacts sleep physiology. Abnormalities in kynurenine pathway metabolism have been reported in various psychiatric and neurological conditions including schizophrenia, [70] [71] [72] [73] [74] mood disorders, [75] [76] [77] [78] and Alzheimer's disease. 79 These disorders are also characterized by distinct hippocampal abnormalities that may contribute to the plaguing cognitive deficits. [80] [81] [82] [83] Sleep disturbances and cognitive dysfunctions, including deficits in learning and memory, are a core domain of several neuropsychiatric disorders, including schizophrenia. [84] [85] [86] Disturbances in sleep can often aggravate illness severity and reduce the quality of life for these patients, 87, 88 and plausible hypotheses suggest that cognitive deficits and abnormal sleep may be connected. 89, 90 The possible role of the kynurenine pathway, and KYNA in particular, [70] [71] [72] [73] in mediating the interplay between sleep and cognitive function in patients with psychiatric disorders remains to be elucidated.
Our findings place new attention on KYNA as both a modulator of cognition and a key molecular mechanism that regulates sleep. It remains to be seen, however, the mechanism by which KYNA may be causally involved in bridging together sleep and cognition, and the pathological processes impacted by this relationship. Our ongoing studies are designed to investigate the impact of reduced KYNA synthesis on sleep and hippocampal memory. Together, these complementary experiments may have significant translational value to treating cognitive impairments and sleep disturbances in health and disease. (25, 50 , 100, or 250 mg/kg) at ZT 0 and were trained in the passive avoidance paradigm at ZT 2. Kynurenine-treated animals showed contextual memory deficits, i.e., reduced fold change in testing day latency over training day latency. Data are mean ± SEM. *p < .05, **p < .01 versus vehicle; N = 8 − 14 per group. ZT: zeitgeber time.
